Kyverna Therapeutics announced one-year data from its KYSA-8 trial showing that miv-cel, a CAR T-cell therapy, significantly improves mobility and reduces disability in patients with stiff person syndrome (SPS). The single-dose treatment demonstrated durable efficacy across multiple measures, with most patients remaining off chronic immunotherapies and experiencing improved physical and mental health. The therapy showed a favorable safety profile with no severe side effects like high-grade CRS or ICANS. These results support miv-cel's potential as the first approved treatment for SPS and a breakthrough CAR T-cell therapy for autoimmune diseases.
Kyverna Therapeutics data on miv-cel in stiff person syndrome offers context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 21, 2026 18:11 WIB: 71 of 150 health-sector US stocks rose, 67 fell. Notable movers include TWST at USD 137.09 with 0% sell and 100% buy activity, TNGX at USD 26.20 up 3.76%, and BAX at USD 25.30 up 3.22%.
The Human Feedback Foundation, supported by RBC, has launched the Agentic AI Design Exchange, a national program aimed at helping Canadian nonprofits design, build, and deploy AI agents responsibly. Funded through RBC's Stronger Nonprofits Program, t...
Satellos Bioscience Inc., a clinical-stage company focused on treatments for degenerative muscle diseases, announced its management will participate in two investor conferences in November: the Guggenheim Healthcare Innovation Conference on Nov 9 in ...
YYForce Inc. has purchased 20 wearable data collection systems to gather real task data from hotel room service at Novotel Singapore. This project aims to record and analyze experienced staff performing tasks like bed-making, towel folding, and clean...
The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, at a compound annual growth rate of 20.2%. This growth is driven by increasing demand for chronic disease managem...
The global private credit and alternative lending market, valued at $2.31 trillion in 2026, is expected to grow at a 7.8% CAGR to reach $3.36 trillion by 2031. Recent liquidity pressures in 2025, triggered by bankruptcies and AI sector concerns, caus...
